| Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy RA Morgan, N Chinnasamy, D Abate-Daga, A Gros, PF Robbins, Z Zheng, ... Journal of immunotherapy 36 (2), 133-151, 2013 | 1281 | 2013 |
| Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand B Bielekova, B Goodwin, N Richert, I Cortese, T Kondo, G Afshar, B Gran, ... Nature medicine 6 (10), 1167-1175, 2000 | 994 | 2000 |
| Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis B Bielekova, M Catalfamo, S Reichert-Scrivner, A Packer, M Cerna, ... Proceedings of the National Academy of Sciences 103 (15), 5941-5946, 2006 | 720 | 2006 |
| Development of biomarkers in multiple sclerosis B Bielekova, R Martin Brain 127 (7), 1463-1478, 2004 | 404 | 2004 |
| Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β B Bielekova, N Richert, T Howard, G Blevins, S Markovic-Plese, ... Proceedings of the National Academy of Sciences 101 (23), 8705-8708, 2004 | 394 | 2004 |
| Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis B Bielekova, MH Sung, N Kadom, R Simon, H McFarland, R Martin The Journal of Immunology 172 (6), 3893-3904, 2004 | 313 | 2004 |
| A role for interleukin-2 trans-presentation in dendritic cell–mediated T cell activation in humans, as revealed by daclizumab therapy SC Wuest, JH Edwan, JF Martin, S Han, JSA Perry, CM Cartagena, ... Nature medicine 17 (5), 604-609, 2011 | 311 | 2011 |
| Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease B Hemmer, B Gran, Y Zhao, A Marques, J Pascal, A Tzou, T Kondo, ... Nature medicine 5 (12), 1375-1382, 1999 | 289 | 1999 |
| Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease R Bomprezzi, M Ringner, S Kim, ML Bittner, J Khan, Y Chen, A Elkahloun, ... Human molecular genetics 12 (17), 2191-2199, 2003 | 249 | 2003 |
| Mechanisms of immunomodulation by glatiramer acetate B Gran, LR Tranquill, M Chen, B Bielekova, W Zhou, S Dhib–Jalbut, ... Neurology 55 (11), 1704-1714, 2000 | 236 | 2000 |
| Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments AM Weideman, MA Tapia-Maltos, K Johnson, M Greenwood, B Bielekova Frontiers in neurology 8, 296533, 2017 | 233 | 2017 |
| Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis B Bielekova, T Howard, AN Packer, N Richert, G Blevins, J Ohayon, ... Archives of neurology 66 (4), 483-489, 2009 | 216 | 2009 |
| Complex immunomodulatory effects of interferon‐β in multiple sclerosis include the upregulation of T helper 1‐associated marker genes KP Wandinger, CS Stürzebecher, B Bielekova, G Detore, A Rosenwald, ... Annals of Neurology: Official Journal of the American Neurological …, 2001 | 216 | 2001 |
| Evolution of the blood–brain barrier in newly forming multiple sclerosis lesions MI Gaitán, CD Shea, IE Evangelou, RD Stone, KM Fenton, B Bielekova, ... Annals of neurology 70 (1), 22-29, 2011 | 190 | 2011 |
| Retinoid X receptor activation reverses age-related deficiencies in myelin debris phagocytosis and remyelination MS Natrajan, AG de la Fuente, AH Crawford, E Linehan, V Nunez, ... Brain 138 (12), 3581-3597, 2015 | 176 | 2015 |
| Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis W Jiang, NR Chai, D Maric, B Bielekova The Journal of Immunology 187 (2), 781-790, 2011 | 167 | 2011 |
| Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis JSA Perry, S Han, Q Xu, ML Herman, LB Kennedy, G Csako, B Bielekova Science translational medicine 4 (145), 145ra106-145ra106, 2012 | 161 | 2012 |
| An IL-2 paradox: blocking CD25 on T cells induces IL-2–driven activation of CD56bright NK cells JF Martin, JSA Perry, NR Jakhete, X Wang, B Bielekova The Journal of Immunology 185 (2), 1311-1320, 2010 | 143 | 2010 |
| Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis M Komori, YC Lin, I Cortese, A Blake, J Ohayon, J Cherup, D Maric, ... Annals of clinical and translational neurology 3 (3), 166-179, 2016 | 142 | 2016 |
| Monoclonal antibodies in MS: mechanisms of action B Bielekova, BL Becker Neurology 74 (1_supplement_1), S31-S40, 2010 | 138 | 2010 |
